Treatment(s) already received-Radiation - Page 3 of 9 Posts on Medivizor
Navigation Menu

Treatment(s) already received-Radiation Posts on Medivizor

Chemoradiation and hypothyroidism in patients with Hodgkin Lymphoma.

Chemoradiation and hypothyroidism in patients with Hodgkin Lymphoma.

Posted by on Sep 15, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the development of hypothyroidism in patients with Hodgkin lymphoma after chemoradiation therapy. Patients were more likely to develop hypothyroidism after intensity modulated radiation therapy than after 3-dimensional conformal radiation therapy. Some background Patients with Hodgkin lymphoma (HL) are commonly...

Read More

Evaluating the risk of developing acute myeloid leukemia or myelodysplastic syndrome after a stem cell transplant

Evaluating the risk of developing acute myeloid leukemia or myelodysplastic syndrome after a stem cell transplant

Posted by on Sep 4, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the risk of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) development in patients with lymphoma and myeloma after an autologous stem cell transplant (autoSCT). This study concluded that this risk is quite high after autoSCT in these patients. Some background AML and MDS are known long-term...

Read More

Evaluating the risk of developing acute myeloid leukemia or myelodysplastic syndrome after a stem cell transplant

Evaluating the risk of developing acute myeloid leukemia or myelodysplastic syndrome after a stem cell transplant

Posted by on Sep 4, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the risk of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) development in patients with lymphoma and myeloma after an autologous stem cell transplant (autoSCT). This study concluded that this risk is quite high after autoSCT in these patients. Some background AML and MDS are known long-term...

Read More

Overall survival and relapse rate in adults with AML who have received a stem cell transplant from a donor

Overall survival and relapse rate in adults with AML who have received a stem cell transplant from a donor

Posted by on Aug 1, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to identify the outcomes and prognostic factors following a stem cell transplant from a donor in adults with acute myeloid leukemia in their second complete remission (no sign of disease). The authors determined that this type of transplant was effective in these patients. Some background In adult patients with acute...

Read More

Risk of secondary cancers in patients who have been treated for early stage breast cancer

Risk of secondary cancers in patients who have been treated for early stage breast cancer

Posted by on May 17, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to examine the risk of developing a secondary cancer after breast conserving therapy for early stage breast cancer patients. This study found that patients who have been treated for early stage breast cancer do not have a significantly higher risk of secondary cancers.  Some background Women with early stage breast...

Read More

What are the long-term outcomes for HL patients receiving plerixafor before a stem cell transplant?

What are the long-term outcomes for HL patients receiving plerixafor before a stem cell transplant?

Posted by on May 7, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared the long-term outcomes of Hodgkin’s lymphoma (HL) patients who received plerixafor (Mozobil) to those who did not prior to autologous stem cell transplantation (autoSCT). This study concluded that plerixafor-treated patients had similar outcomes as patients who received conventional regimens. Some background...

Read More

Can white blood cell count ratios help predict outcomes for newly diagnosed HL patients receiving PET2-mediated treatment?

Can white blood cell count ratios help predict outcomes for newly diagnosed HL patients receiving PET2-mediated treatment?

Posted by on Apr 6, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the impact of white blood cell counts on the outcomes of newly diagnosed Hodgkin’s lymphoma (HL) patients receiving treatment mediated by PET2 (PET scanning after 2 cycles of chemotherapy). This study concluded that ratios of different types of white blood cells combined with PET2 can be a meaningful...

Read More

Breast conserving surgery in combination with intra-operative radiotherapy is an option for patients with recurrence of breast cancer who have previously had chest irradiation

Breast conserving surgery in combination with intra-operative radiotherapy is an option for patients with recurrence of breast cancer who have previously had chest irradiation

Posted by on Mar 5, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to examine breast conserving surgery (BCS) in combination with intra-operative radiotherapy (IORT) for patients who have previously had radiation treatment to the chest. This study found that BCS in combination with IORT provides good local control and overall survival in patients with previous chest...

Read More

Risk of developing breast cancer among female Hodgkin lymphoma patients

Risk of developing breast cancer among female Hodgkin lymphoma patients

Posted by on Feb 27, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at the risk of developing breast cancer while on hormone replacement therapy for female patients who were treated with radiation for Hodgkin lymphoma. The authors concluded that radiation therapy significantly increased the risk of developing breast cancer, and hormone replacement therapy did not significantly increase the...

Read More

PSA response after cabazitaxel treatment is associated with improved progression-free survival in men with metastatic castration-resistant prostate cancer.

PSA response after cabazitaxel treatment is associated with improved progression-free survival in men with metastatic castration-resistant prostate cancer.

Posted by on Jan 26, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to examine the links between prostate specific antigen (PSA, a protein present in prostate cancer) and survival in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel. This studty concluded that PSA response after cabazitaxel treatment is associated with improved...

Read More

Radiotherapy, chemo, and second cancers: what is the risk in Hodgkin lymphoma?

Radiotherapy, chemo, and second cancers: what is the risk in Hodgkin lymphoma?

Posted by on Nov 17, 2017 in Hodgkin's lymphoma | 0 comments

In a nutshell This review explored the risk of developing a secondary cancer after being treated for Hodgkin lymphoma with chemotherapy and/or radiotherapy. The review concluded that intensified chemotherapy and radiotherapy are more effective but are associated with a greater risk of developing a secondary cancer.  Some background Hodgkin...

Read More

An analysis of abiraterone plus prednisone for metastatic castration-resistant prostate cancer

An analysis of abiraterone plus prednisone for metastatic castration-resistant prostate cancer

Posted by on Nov 8, 2017 in Prostate cancer | 0 comments

In a nutshell This study aimed to determine which patients  benefited most from abiraterone acetate (Zytiga) and prednisone (Deltasone). This study found that overall survival was increased for all patient groups that received this combination.  Some background A main treatment option for prostate cancer is androgen deprivation...

Read More